Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) — Capital Reinvestment Ratio
Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has a Capital Reinvestment Ratio of 1.89x as of December 2023, meaning it reinvests 2% of its operating cash flow (CN¥37.03 Million) in capital expenditures (CN¥70.15 Million). See cash generation quality of Shandong Keyuan Pharmaceutical Co. Ltd. to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Shandong Keyuan Pharmaceutical Co. Ltd. A Capital Reinvestment Ratio (2021–2023)
This chart tracks Shandong Keyuan Pharmaceutical Co. Ltd. A's Capital Reinvestment Ratio across 3 annual periods.
Annual Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A (2021–2023)
Year-by-year Capital Reinvestment Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A from 2021 to 2023. For live market cap and broader valuation context, see Shandong Keyuan Pharmaceutical Co. Ltd. market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2023 | 1.89x | CN¥37.03 Million | CN¥70.15 Million | ▲ +605.5% |
| 2022 | 0.27x | CN¥115.86 Million | CN¥31.11 Million | ▼ -30.8% |
| 2021 | 0.39x | CN¥52.02 Million | CN¥20.19 Million | — |